Arkadios Wealth Advisors Sells 185 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Arkadios Wealth Advisors trimmed its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,753 shares of the company’s stock after selling 185 shares during the period. Arkadios Wealth Advisors’ holdings in HealthEquity were worth $456,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in HQY. Holocene Advisors LP bought a new position in shares of HealthEquity during the third quarter valued at about $1,246,000. GSA Capital Partners LLP purchased a new stake in shares of HealthEquity during the third quarter valued at approximately $638,000. Natixis Advisors LLC lifted its holdings in HealthEquity by 29.8% during the third quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock worth $17,122,000 after acquiring an additional 48,009 shares during the period. Vaughan Nelson Investment Management L.P. boosted its position in HealthEquity by 36.7% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after purchasing an additional 226,563 shares during the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in HealthEquity by 2.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company’s stock valued at $92,216,000 after purchasing an additional 24,665 shares during the period. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Frank Corvino sold 1,039 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the sale, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. This trade represents a 21.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the completion of the transaction, the director now directly owns 19,061 shares of the company’s stock, valued at approximately $1,843,579.92. This represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,289 shares of company stock worth $3,355,718. Corporate insiders own 2.20% of the company’s stock.

HealthEquity Stock Up 2.3 %

HQY stock opened at $104.74 on Wednesday. The stock has a 50-day simple moving average of $99.04 and a two-hundred day simple moving average of $86.92. HealthEquity, Inc. has a twelve month low of $65.01 and a twelve month high of $105.82. The firm has a market capitalization of $9.08 billion, a PE ratio of 96.09, a PEG ratio of 1.80 and a beta of 0.54. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same quarter in the previous year, the firm posted $0.40 EPS. On average, equities analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HQY. The Goldman Sachs Group began coverage on HealthEquity in a research note on Friday, November 15th. They set a “neutral” rating and a $108.00 target price on the stock. Royal Bank of Canada lifted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. BTIG Research increased their target price on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Mizuho initiated coverage on shares of HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price target on the stock. Finally, Barrington Research increased their price objective on HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.71.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.